Compare REX AI Equity Premium Income ETF (AIPI) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Boston Scientific Corporation — how do they compare? REX AI Equity Premium Income ETF trades at $36.26, while Boston Scientific Corporation trades at $44.65 (market cap $67.33B). The key difference: REX AI Equity Premium Income ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| AIPI | BSX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $108.14 |
52-Week Low | $32.45 | $42.68 |
Market Cap | — | $67.33B |
Enterprise Value | — | $76.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
Boston Scientific (BSX) trades at $45.30, showing modest daily gains of 0.35% amid a bearish technical trend. The company demonstrates strong fundamentals with consistent earnings beats, revenue growth from $12.7B in 2022 to $20.1B in 2025, and robust profitability margins. Recent news highlights a significant price decline from all-time highs, creating valuation opportunities despite competitive pressures in key segments like electrophysiology.
The investment outlook remains positive based on strong analyst consensus (88% buy ratings) and a $73.63 price target implying 63% upside. Key risks include growth deceleration in core products and market volatility. Fundamentals support long-term value, but investors should monitor execution against revised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
